All Access

Biotech Deals

Biotech Deals Alert

Alert

BioMarin Pharmaceutical agreed to buy rare disease biotech Amicus Therapeutics for about $4.8 billion.

What's next: BioMarin wants to do more smaller-scale acquisitions, CEO Alexander Hardy told Bloomberg.

By the numbers: Amicus (Nasdaq: FOLD) shares will swap for $14.50 a share in cash, a 33% premium to the last closing price. 

BioMarin (Nasdaq: BMRN) rose more than 20% today on the news. 

Zoom in: The deal gives BioMarin access to Amicus' treatments for Fabry disease and Pompe disease.

BioMarin's top-selling drug is Voxzogo, a treatment for a type of dwarfism known as achondroplasia.

State of play: The rare disease space has seen Big Pharma-led takeovers and hundreds of millions of dollars in venture capital funding.

Sanofi agreed to buy rare immunology disease company Blueprint Medicines for up to $9.1 billion in June. 

Mirum Pharmaceuticals (Nasdaq: MIRM) agreed to buy biotech Bluejay Therapeutics in a deal worth up to $820 million this month.

Companies like Star Therapeutics and Protego Biopharma raised triple-digit rounds this year.

Catch up quick: In May, Amicus inked a $560 million licensing deal with Dimerix for a rare kidney disease treatment.

The same month, BioMarin acquired Inozyme Pharma in a deal worth about $270 million to for a late-stage treatment for a condition impacting blood vessels, soft tissues and bones.

BioMarin to acquire Amicus Therapeutics for $4.8B

BioMarin wants to do more smaller-scale acquisitions, its CEO says.

Illustration of people shaking hands with pill bottles as sleeves.

BioMarin Pharmaceutical agreed to buy <a class="gtmContentClick" data-vars-link-text="rare disease" data-vars-click-url="https://www.axios.com/pro/biotech-deals/2025/09/05/fda-rare-disease-framework-dealmaking" data-vars-content-id="32c25d4c-ca04-45ac-98c2-f9f016686c4b" data-vars-headline="BioMarin to acquire Amicus Therapeutics for $4.8B" data-vars-event-category="story" data-vars-sub-category="story" data-vars-item="in_content_link" href="https://www.axios.com/pro/biotech-deals/2025/09/05/fda-rare-disease-framework-dealmaking" target="_self">rare disease</a> biotech Amicus Therapeutics for about $4.8 billion.What&#x27;s next: BioMarin wants to do more smaller-scale acquisitions, CEO Alexander Hardy <a class="gtmContentClick" data-vars-link-text="told Bloomberg" data-vars-click-url="https://www.bloomberg.com/news/articles/2025-12-19/biomarin-to-buy-amicus-in-4-8-billion-bet-on-rare-disease-drugs?srnd=phx-deals" data-vars-content-id="32c25d4c-ca04-45ac-98c2-f9f016686c4b" data-vars-headline="BioMarin to acquire Amicus Therapeutics for $4.8B" data-vars-event-category="story" data-vars-sub-category="story" data-vars-item="in_content_link" href="https://www.bloomberg.com/news/articles/2025-12-19/biomarin-to-buy-amicus-in-4-8-billion-bet-on-rare-disease-drugs?srnd=phx-deals" target="_blank">told Bloomberg</a>.

topics

politics-policy

epstein-files

donald-trump

2026-midterm-elections

immigration

behind-the-curtain

race-and-equity

technology

privacy-tech-regulation

automation-and-ai

tiktok-news

big-tech

social-media

cybersecurity

economy

social-security

inflation

tariffs

federal-reserve

jobs

transportation

business

stock-market-news

retail-news

crypto

media

elon-musk

dealmaking

health

rfk-jr

drug-prices

axios-explains-abortion

public-health

world

israel

axios-explains-ukraine

iran

russia

china

energy-climate

nuclear-energy

climate-energy-policy

climate-change

extreme-weather

alternative-energy

electric-vehicles

science

emerging-tech

biomedicine

newsletters

charlotte

boulder

detroit

kansas-city

columbus

austin

dallas

atlanta

washington-dc

nw-arkansas

chicago

indianapolis

nashville

richmond

colorado-springs

houston

san-francisco

seattle

boston

des-moines

salt-lake-city

philadelphia

denver

phoenix

new-orleans

miami

twin-cities

raleigh

san-antonio

portland

san-diego

tampa-bay

cleveland

huntsville

pittsburgh

axios-local

axios-pro

axios-live

the-axios-show

BioMarin to acquire Amicus Therapeutics for $4.8B

What to read next